1. Severity Index of Acquired Community Pneumonia (it will be evaluated for each patient included in the study and globally, measured by the sum of patients with treatment evaluation (significantly effective + effective) divided by the total number of patients and multiplied by 100). a) Significantly effective: the severity decreases by two levels, always compared to the result of the previous evaluation. b) Effective: the severe decrees in one level, always compared to the result of the previous evaluation. c) Not effective: not chance or progress to the Severe Respiratory Distress). Measurement time: At the beginning and, on the 10th day of starting treatment,
2. Standardized Mortality Rate (It is the ratio between the number of observed deaths and the number of expected deaths, according to the risk of death calculated by APACHE II. The adjusted or “standardized” rate). Measurement time: At the 10th day of treatment at the time of discharge from the Critical Care Unit.
3. Adverse Events (It will describe type, time, intensity, causal relationship, behavior taken and result). Measurement time: At the beginning, 48 hours, 72 hours, 96 hours, 7th day and 10th day, after to start of treatment
4. Intrahospitalary and discharge mortality (Proportion of severe patients to died (global and by doses), even to cause and groups of treatment). Measurement time: During the hospitalary time or at discharge at 28 days, from to start the treatment with Jusvinza.
5. Necessity and time of non-invasive machanical ventilation and/or oxygen-therapy (Need for oxygen support or non-invasive mechanical ventilation (Yes, No) and time since the patient needs oxygen support or non-invasive mechanical ventilation until the withdrawal of oxygenation or non-invasive mechanical ventilation or until the moment in which the patient requires endotracheal intubation). Measurement time: Upon withdrawal of oxygenation or non-invasive mechanical ventilation or until such time as the patient requires endotracheal intubation.
6. Time to invasive mechanical ventilation (Time, from the patient is intubated up to finish to endotracheal intubation). Measurement time: At the endotracheal intubation is removed;
7. Time up to endotracheal intubation (Time, in days, between the start of treatment with Jusvinza, with the patient in a serious condition, until the moment in which the patient requires endotracheal intubation). Measurement time: At the end of the endotracheal intubation procedure
8. Global SOFA (Scale SOFA. It will provide dynamic data on the patient's status, in relation to organ function (respiratory, cardiovascular, liver, coagulation, kidney and neurological). The zero value is compatible with adequate organ function, between 1 and 2 dysfunction and between 3 and 4 organ failure points). Measurement time: daily during the patient's stay in the unit.
9. Reduction in lung function decline (Proportion of patients, intubated or not, who did not require an increase in FiO2 to maintain stable SO2 and/or Percentage of patients who decreased positive end-expiratory pressure values: PEEP = 5 cm H2O). Measurement time: At 72 hours, 96 hours, 7th day, and 10th day after starting treatment.
10. Stay in the Serious Patient Care Unit (Time, in days, from inclusion in the trial to discharge from the Serious Patient Care Unit). Measurement time: At discharge of the Serious Patient Care Unit.
11. Overall hospital stay (Time from hospital admission up to hospital discharge). Measurement time: At hospital discharge.
12. Immunological evaluation (Quantification of proinflammatory cytokines: quantification of proinflammatory cytokines: IL-6, TNFα and Calprotectin, through a commercial ELISA). Measurement time: At the beginning, at 96 hours, and 10th day, from the start of treatment.
13. Quantification of T-regulatory cells (phenotype CD4+, CD25h, CD127- in the blood). Measurement time: At the beginning and at the end of treatment.
14. Behavior of biomarkers (Absolute lymphocyte count, mesurement C-reactive protein, erythrocyte sedimentation rate and lactate dehydrogenase – LDH). Measurement time: At the beginning and at 72 hours, 96 hours, 7th day and 10th day of starting treatment in the Serious Patient Care Unit. However, the biomarkers will be performed whenever the patient's condition requires it.
15. Imaging response (The evolution of the pulmonary lesions will be evaluated by chest X-ray and CT: if it is possible to perform the latter). Measurement time: At the beginning, 72 hours, 7th day and 10th day after starting treatment. Imaging will be performed whenever the patient's serious condition requires it.
